Using prognostic biomarkers such as overexpression of HER2 for breast cancer [2], it is possible to subgroup patients for certain types of cancer into populations with distinct risk profiles and design optimal treatment regimens for the heterogeneous subtypes of cancer [3]. Here, ERBB2 is linked to cancer.